-
Regulatory uncertainty brings risk and opportunity to pharma in 2025, says Jeff Lemay
CCO Jeff Lemay reflects on his time at Jazz Pharmaceuticals and asseses the road ahead for compliance and legal teams in the pharma sector.
-
Suspending the FCPA will complicate global anti-corruption work
Will UK and Europe step up to the plate after Trump’s suspension of crucial anti-corruption legislation, asks Tony McClements?
-
FCPA trial almost started, but DOJ’s suspension of new FCPA cases lingers
The FCPA enforcement action against Cognizant is going forward despite President Trump’s Executive Order.
-
OPINION: FCPA ‘pause’ is a self-inflicted setback that undermines US competitiveness
Pat Poitevin explores the real-world consequences of pausing the FCPA.
-
Trump halts enforcement of FCPA, directs AG Bondi to revise guidance
The anti-bribery law has undergirded landmark DOJ cases, including one against Goldman Sachs for over $2.9 billion in penalties in 2020.
-
Memoranda from AG Bondi signal huge shifts in priorities
AG Pam Bondi issued a series of directives aimed at aligning the department with President Trump’s agenda, including changes to the DOJ’s approach to FCPA enforcement.
-
SEC on a tear: Seven decisions, from FCPA scheming to MNPI reporting
Several SEC cases highlight its effort to clear its docket, plus remind firms of internal controls principles and registration and reporting basics.
-
GRIP Extra: Gensler and Lizárraga out at SEC, Hwang gets 18 years
Other news includes Microsoft state cyberattack appeals, greenwashing claims against Canadian banks, Northvolt files for bankruptcy and Chinese firms expand California presence.